Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) – Analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of Kodiak Sciences in a research report issued to clients and investors on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will earn ($1.10) per share for the quarter, up from their previous forecast of ($1.13). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01.
Check Out Our Latest Research Report on KOD
Kodiak Sciences Price Performance
Shares of KOD stock opened at $3.74 on Friday. The stock has a 50 day simple moving average of $2.76 and a 200-day simple moving average of $2.95. Kodiak Sciences has a 1-year low of $1.37 and a 1-year high of $7.77. The company has a market cap of $196.48 million, a price-to-earnings ratio of -0.84 and a beta of 2.34.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Diversified Trust Co purchased a new stake in Kodiak Sciences during the 1st quarter valued at about $83,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $68,000. RIA Advisory Group LLC acquired a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $489,000. Susquehanna Fundamental Investments LLC purchased a new position in Kodiak Sciences during the first quarter worth approximately $236,000. Finally, Sei Investments Co. acquired a new position in Kodiak Sciences during the first quarter worth $595,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
- Five stocks we like better than Kodiak Sciences
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Healthcare Dividend Stocks to Buy
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.